How Much Will Retatrutide Cost When Approved? 2026-2028 Honest Forecast
Updated 2026-05-06 · 14 min read · Forecast based on Wegovy/Zepbound benchmarks
⚠️ Critical disclaimer
Retatrutide is NOT FDA-approved and has NO commercial price in 2026. Every dollar figure in this article is a projection based on Wegovy and Zepbound launch pricing — anchors that may or may not predict retatrutide's actual launch price. Anyone selling "retatrutide" commercially in 2026 is operating outside FDA-approved channels. We do not link to any such vendor.
TL;DR — Most likely scenarios
- 💊 FDA-approved branded retatrutide (forecast): $1,000-1,500/month list price at launch (estimate based on Wegovy/Zepbound).
- 🏥 With insurance (forecast): $25-200/month with savings card or PA approval (similar to Zepbound today).
- 🏪 Compounded retatrutide: Currently UNAVAILABLE legally. May or may not exist post-approval depending on patent enforcement and 503A pharmacy willingness. IF available: $300-600/month estimate — highly speculative.
- 🌐 Telehealth providers (forecast): $200-400/month if compounded route opens. $99-150/month membership + branded medication separate (current SHED model).
- 💰 Direct without insurance (forecast): $1,300+/month likely.
- 🕐 Available WHEN: 2027-2028 estimated. NOT 2026.
So what does retatrutide “cost” TODAY in 2026?
Before the forecast, the honest present-day answer: there is no official, approved price because there is no approved product. What you’ll find online are three very different routes — and the cheapest ones carry the most risk.
| Route | Rough monthly range | Reality check |
|---|---|---|
| Research “peptides” (online vendors) | ~$150–$400 | Not for human use. No quality control, often imported, legally gray to illegal. Cheap for a reason. |
| Compounding pharmacies | Was ~$300–$600 | Channel is closing. FDA’s 2026 503A/503B actions are shutting down large-scale compounding. |
| Clinical trials | $0 (if you qualify) | Free, supervised — but limited slots and strict criteria. |
Approximate ranges per public 2026 reports — directional, not a recommendation to buy, and subject to change.
⚠️ The “cheap Chinese peptide” trap
The lowest prices you’ll see come from unregulated research-peptide vendors. Independent reporting in 2026 has repeatedly flagged these as a safety risk: unknown purity, no medical supervision, and no recourse if something goes wrong. Cheaper is not safer. Paying less for an unverified injectable is the most expensive mistake you can make with your health. We do not link to any such vendor.
📜 2026 update: the legal compounding door is closing
The FDA’s April 2026 503A clarification and the May 2026 503B proposal are designed to shut down the large-scale compounding channel many GLP-1 users relied on. That matters for retatrutide: even if a compounded route appears post-approval, it may be far more restricted than the semaglutide/tirzepatide compounding market of 2024–2025. Plan around legal, supervised options.
Why we don't know exactly yet
Retatrutide is still in Phase 3 trials (the TRIUMPH program). Eli Lilly has not announced launch pricing because the FDA has not approved the molecule yet. Until the New Drug Application (NDA) is accepted, FDA review completes, and Lilly officially launches the drug, the only thing we can do is forecast based on precedent.
Pharmaceutical pricing in the U.S. is influenced by: (1) the manufacturer's strategy (premium positioning vs market share), (2) competitive landscape (how many alternatives exist at launch), (3) insurance coverage decisions (which depend on cost-effectiveness analyses), (4) patient assistance programs (PAPs), and (5) 340B / Medicaid pricing requirements. Each variable is uncertain until launch.
Pricing benchmarks: how Wegovy & Zepbound priced at launch
| Drug | Manufacturer | Launch year | List price/month | With savings card |
|---|---|---|---|---|
| Wegovy (semaglutide) | Novo Nordisk | 2021 | ~$1,349 | ~$0-650 commercially insured |
| Zepbound (tirzepatide) | Eli Lilly | 2023 | ~$1,059 | ~$25-550 commercially insured |
| Retatrutide (forecast) | Eli Lilly | 2027-2028 est | $1,000-1,500 est | ~$25-700 est |
Wegovy and Zepbound prices from public manufacturer sources, Lilly Direct, GoodRx, NovoCare. Retatrutide row is speculative forecast based on these anchors.
3 likely launch pricing scenarios
Scenario 1 — Premium pricing (most likely)
List price: $1,200-1,500/month. Lilly's strategy with novel mechanisms tends toward premium positioning. Retatrutide is the FIRST triple agonist. Lilly captures price for innovation.
Probability: ~50%
Scenario 2 — Match Zepbound pricing
List price: $1,000-1,100/month. Lilly may price retatrutide at parity with Zepbound to drive faster adoption and protect Zepbound users from switching shock. Especially likely if FDA labels are similar.
Probability: ~30%
Scenario 3 — Aggressive disruption pricing
List price: $800-1,000/month. If GLP-1 market becomes commoditized by 2027-2028 (multiple branded options + compounded competition), Lilly may launch retatrutide at lower price to win volume. Less likely without obvious competition pressure.
Probability: ~20%
Insurance and patient assistance forecast
Wegovy and Zepbound followed similar patterns: launch with limited insurance coverage (mostly self-funded employer plans), expand to commercial insurance over 18-24 months, gradual Medicare Part D inclusion (limited), state Medicaid coverage varies wildly.
For retatrutide:
- 📋 Year 1 (2027-2028): Patient assistance programs (Lilly savings card) reduce out-of-pocket to ~$25-100/month for commercially insured patients. Without insurance: full list price.
- 📋 Year 2 (2028-2029): Broader insurance coverage as cost-effectiveness data accumulates. Prior authorization (PA) standard. BMI cutoffs typical (e.g., BMI ≥30 or ≥27 with comorbidities).
- 📋 Medicare: Currently does NOT cover obesity drugs by statute. Active legislative effort to change this. If Medicare opens, demand spike likely.
- 📋 Medicaid: Varies by state. Some cover Wegovy/Zepbound now; retatrutide will likely follow same state-by-state pattern.
Get notified when retatrutide pricing is announced
We track Lilly press releases, payer coverage, and savings program launches. One alert per material milestone — no spam.
Affordable GLP-1 options available TODAY (while you wait)
Retatrutide is years away. If your doctor recommends starting a GLP-1 NOW, currently available options include compounded semaglutide and tirzepatide via 503A pharmacy telehealth platforms. Honest comparison:
SkinnyRx
Most affordable
Compounded semaglutide ~$179 first month, ~$199-249/mo ongoing. Multiple formats. (Affiliate link — see disclosure.)
View SkinnyRx →SHED
Best balance + 10% guarantee
Compounded semaglutide + tirzepatide + supplements + 1-on-1 coaching. ~$199-299/mo. 10% loss guarantee. (Affiliate link.)
View SHED →GobyMeds
Most personal support
Compounded semaglutide ~$199-349/mo with monthly check-ins. Strong support model. (Affiliate link.)
View GobyMeds →Affiliate link · Educational · Talk to your doctor. We earn a commission at no cost to you when readers subscribe through our tracking links. See full FTC disclosure.
For deeper comparison, see our Best GLP-1 Telehealth Programs 2026 review and SkinnyRx vs Hims head-to-head analysis.
Frequently asked
How much does retatrutide cost in 2026?
Retatrutide has no commercial price in 2026 because it is NOT yet FDA-approved. Anyone selling "retatrutide" commercially in 2026 is operating outside FDA-approved channels.
Will insurance cover retatrutide when approved?
Likely partial coverage in 2027-2028, similar to Wegovy and Zepbound trajectory. PA requirements common. Coverage varies by insurer, plan, and BMI/comorbidity criteria.
Will compounded retatrutide be available cheaper?
Uncertain. Depends on Lilly patent enforcement, FDA shortage list status, and 503A pharmacy willingness. As of 2026, NO legal compounded retatrutide exists.
What's the cheapest GLP-1 option TODAY in 2026?
Currently available compounded semaglutide via 503A telehealth (~$179-249/mo at programs like SkinnyRx, GobyMeds, SHED). FDA-approved options $1,000-1,400/mo without insurance.
How does Wegovy/Zepbound pricing inform retatrutide pricing?
Wegovy launched ~$1,349/mo (Novo, 2021). Zepbound launched ~$1,059/mo (Lilly, 2023). Retatrutide will likely launch in $1,000-1,500/mo range as premium next-generation. Speculative until launch.
Sources
- Wegovy and Zepbound list pricing: Novo Nordisk corporate communications, Lilly Direct, GoodRx, NovoCare patient assistance pages.
- Retatrutide regulatory status: ClinicalTrials.gov NCT05882045 (TRIUMPH-4); Eli Lilly investor disclosures 2025-2026.
- Retatrutide Phase 2: Jastreboff AM et al, NEJM 2023, PMID 37364103.
- FDA Orange Book and 503A compounding guidance: FDA.gov.
Disclaimer: All retatrutide pricing in this article is FORECAST/PROJECTION. Retatrutide is investigational and NOT FDA-approved. Currently no legal commercial price exists. Wegovy and Zepbound figures are publicly verifiable as of 2026. Forecasts may be revised as new information becomes available.